Latest Insider Transactions at Oncology Institute, Inc. (TOI)
This section provides a real-time view of insider transactions for Oncology Institute, Inc. (TOI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Oncology Institute, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Oncology Institute, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 15
2022
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
16,663
-0.11%
|
$99,978
$6.23 P/Share
|
|
Aug 12
2022
|
Havencrest Healthcare Partners, L.P. |
SELL
Open market or private sale
|
Indirect |
24,900
-0.16%
|
$149,400
$6.69 P/Share
|
|
May 19
2022
|
Mihir Shah Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,121
+50.0%
|
-
|
|
May 11
2022
|
Richy Agajanian > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,600,000
-33.81%
|
$9,600,000
$6.0 P/Share
|
|
Mar 21
2022
|
Karen Marie Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,792
+34.37%
|
-
|
|
Mar 21
2022
|
Anne Mc George Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,391
+36.11%
|
-
|
|
Mar 21
2022
|
Richard A Barasch Director |
BUY
Grant, award, or other acquisition
|
Direct |
45,905
+24.43%
|
-
|
|
Mar 21
2022
|
Matthew P Miller Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,027
+15.83%
|
-
|
|
Mar 21
2022
|
Yale Podnos Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
14,884
+14.66%
|
-
|
|
Mar 21
2022
|
Mohit Kaushal Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,792
+18.6%
|
-
|
|
Mar 21
2022
|
Daniel Virnich Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,015
+15.04%
|
-
|
|
Mar 21
2022
|
Maeve O'Meara Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,992
+33.33%
|
-
|
|
Mar 21
2022
|
Brad Hively Director |
BUY
Grant, award, or other acquisition
|
Direct |
108,469
+19.02%
|
-
|
|
Mar 21
2022
|
Ravi Yang Sarin Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,191
+36.84%
|
-
|
|
Mar 21
2022
|
Scott Dalgleish Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,092
+17.53%
|
-
|
|
Nov 24
2021
|
Richard A Barasch Director |
BUY
Open market or private purchase
|
Direct |
5,000
+1.73%
|
$30,000
$6.96 P/Share
|
|
Nov 23
2021
|
Richard A Barasch Director |
BUY
Open market or private purchase
|
Direct |
5,000
+2.64%
|
$30,000
$6.31 P/Share
|
|
Nov 16
2021
|
Richard A Barasch Director |
BUY
Open market or private purchase
|
Direct |
1,000
+1.15%
|
$10,000
$10.12 P/Share
|
|
Nov 12
2021
|
Dfp Sponsor LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
40
+50.0%
|
-
|
|
Nov 12
2021
|
Mohit Kaushal Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,466
-14.89%
|
-
|
|
Nov 12
2021
|
Mohit Kaushal Director |
BUY
Conversion of derivative security
|
Direct |
30,000
+50.0%
|
-
|
|
Nov 12
2021
|
Daniel Virnich Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
195,236
+43.75%
|
-
|
|
Nov 12
2021
|
Ravi Yang Sarin Director |
BUY
Grant, award, or other acquisition
|
Indirect |
4,109,771
+50.0%
|
-
|
|
Nov 12
2021
|
Scott Dalgleish Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
118,916
+43.75%
|
-
|
|
Nov 12
2021
|
Yale Podnos Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,398
+50.0%
|
-
|
|
Nov 12
2021
|
Richard A Barasch Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,887
-14.89%
|
-
|
|
Nov 12
2021
|
Richard A Barasch Director |
BUY
Conversion of derivative security
|
Direct |
100,000
+50.0%
|
-
|
|
Nov 12
2021
|
James E Flynn > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
85,153
+50.0%
|
-
|
|
Jan 12
2021
|
Brad Hively Director |
BUY
Grant, award, or other acquisition
|
Direct |
353,450
+50.0%
|
-
|
|
Mar 13
2020
|
James E Flynn > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
5,000,000
+50.0%
|
$50,000,000
$10.0 P/Share
|